Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Canadian journal of kidney health and disease. 2022 Jan 7. doi: 10.1177/20543581211069225. pii: 10.1177_20543581211069225. pmc: PMC8744204
    Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury: A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial.
    Garg AX1,  Cuerden M2,  Aguado H3,  Amir M4,  Belley-Cote EP5,  Bhatt K6,  Biccard BM7,  Borges FK8,  Chan M9,  Conen D10,  Duceppe E11,  Efremov S12,  Eikelboom J13,  Fleischmann E14,  Giovanni L15,  Gross P16,  Jayaram R17,  Kirov M18,  Kleinlugtenbelt Y19,  Kurz A20,  Lamy A21,  Leslie K22,  Likhvantsev V23,  Lomivorotov V24,  Marcucci M25,  Martínez-Zapata MJ26,  McGillion M27,  McIntyre W28,  Meyhoff C29,  Ofori S30,  Painter T31,  Paniagua P32,  Parikh C33,  Parlow J34,  Patel A35,  Polanczyk C36,  Richards T37,  Roshanov P38,  Schmartz D39,  Sessler D40,  Short T41,  Sontrop JM42,  Spence J43,  Srinathan S44,  Stillo D45,  Szczeklik W46,  Tandon V47,  Torres D48,  Van Helder T49,  Vincent J50,  Wang CY51,  Wang M52,  Whitlock R53,  Wittmann M54,  Xavier D55,  Devereaux PJ56
    Author information
    1London Health Sciences Centre, ON, Canada.
    2London Health Sciences Centre, ON, Canada.
    3Hospital Clínico Universitario de Valladolid, Spain.
    4Shifa International Hospital (STMU), Islamabad, Pakistan.
    5McMaster University, Hamilton, ON, Canada.
    6SIDS Hospital & Research Centre, Guntur, India.
    7Groote Schuur Hospital, Cape Town, South Africa.
    8Population Health Research Institute, Hamilton, ON, Canada.
    9The Chinese University of Hong Kong, Shatin, Hong Kong.
    10Population Health Research Institute, Hamilton, ON, Canada.
    11Population Health Research Institute, Hamilton, ON, Canada.
    12Saint Petersburg State University, Russia.
    13McMaster University, Hamilton, ON, Canada.
    14Medical University of Vienna, Austria.
    15Istituto Scientifico Universitario San Raffaele, Milan, Italy.
    16McMaster University, Hamilton, ON, Canada.
    17University of Oxford, UK.
    18Northern State Medical University of the Ministry of Healthcare of the Russian Federation, Arkhangelsk, Russia.
    19Deventer Ziekenhuis, The Netherlands.
    20Medical University of Graz, Austria.
    21Population Health Research Institute, Hamilton, ON, Canada.
    22The Royal Melbourne Hospital, VIC, Austria.
    23I. M. Sechenov Moscow Medical Academy, Russia.
    24Novosibirsk State University, Russia.
    25McMaster University, Hamilton, ON, Canada.
    26Centro Cochrane Iberoamericano, Barcelona, Spain.
    27McMaster University, Hamilton, ON, Canada.
    28Population Health Research Institute, Hamilton, ON, Canada.
    29University of Copenhagen, Denmark.
    30Population Health Research Institute, Hamilton, ON, Canada.
    31Royal Adelaide Hospital, SA, Australia.
    32Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
    33Johns Hopkins University, Baltimore, MD, USA.
    34Kingston General Hospital, ON, Canada.
    35McMaster University, Hamilton, ON, Canada.
    36Hospital de Clinicas de Porto Alegre, Brazil.
    37The University of Western Australia, Perth, Australia.
    38Western University, London, ON, Canada.
    39CHU Brugmann, Brussels, Belgium.
    40Cleveland Clinic, OH, USA.
    41Auckland District Health Board, New Zealand.
    42Western University, London, ON, Canada.
    43McMaster University, Hamilton, ON, Canada.
    44University of Manitoba, Winnipeg, Canada.
    45Population Health Research Institute, Hamilton, ON, Canada.
    46Jagiellonian University, Krakow, Poland.
    47McMaster University, Hamilton, ON, Canada.
    48Clinica Santa Maria, Santiago, Chile.
    49Hamilton Health Sciences, ON, Canada.
    50Population Health Research Institute, Hamilton, ON, Canada.
    51University of Malaya, Kuala Lumpur, Malaysia.
    52McMaster University, Hamilton, ON, Canada.
    53Population Health Research Institute, Hamilton, ON, Canada.
    54Universitätsklinikum Bonn, Germany.
    55St. John's National Academy of Health Sciences, Bangalore, India.
    56McMaster University, Hamilton, ON, Canada.
    Abstract

    BACKGROUND: Most patients who take antihypertensive medications continue taking them on the morning of surgery and during the perioperative period. However, growing evidence suggests this practice may contribute to perioperative hypotension and a higher risk of complications. This protocol describes an acute kidney injury substudy of the Perioperative Ischemic Evaluation-3 (POISE-3) trial, which is testing the effect of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy in patients undergoing noncardiac surgery.

    OBJECTIVE: To conduct a substudy of POISE-3 to determine whether a perioperative hypotension-avoidance strategy reduces the risk of acute kidney injury compared with a hypertension-avoidance strategy.

    DESIGN: Randomized clinical trial with 1:1 randomization to the intervention (a perioperative hypotension-avoidance strategy) or control (a hypertension-avoidance strategy).

    INTERVENTION: If the presurgery systolic blood pressure (SBP) is <130 mmHg, all antihypertensive medications are withheld on the morning of surgery. If the SBP is ≥130 mmHg, some medications (but not angiotensin receptor blockers [ACEIs], angiotensin receptor blockers [ARBs], or renin inhibitors) may be continued in a stepwise manner. During surgery, the patients' mean arterial pressure (MAP) is maintained at ≥80 mmHg. During the first 48 hours after surgery, some antihypertensive medications (but not ACEIs, ARBs, or renin inhibitors) may be restarted in a stepwise manner if the SBP is ≥130 mmHg.

    CONTROL: Patients receive their usual antihypertensive medications before and after surgery. The patients' MAP is maintained at ≥60 mmHg from anesthetic induction until the end of surgery.

    SETTING: Recruitment from 108 centers in 22 countries from 2018 to 2021.

    PATIENTS: Patients (~6800) aged ≥45 years having noncardiac surgery who have or are at risk of atherosclerotic disease and who routinely take antihypertensive medications.

    MEASUREMENTS: The primary outcome of the substudy is postoperative acute kidney injury, defined as an increase in serum creatinine concentration of either ≥26.5 μmol/L (≥0.3 mg/dL) within 48 hours of randomization or ≥50% within 7 days of randomization.

    METHODS: The primary analysis (intention-to-treat) will examine the relative risk and 95% confidence interval of acute kidney injury in the intervention versus control group. We will repeat the primary analysis using alternative definitions of acute kidney injury and examine effect modification by preexisting chronic kidney disease, defined as a prerandomization estimated glomerular filtration rate <60 mL/min/1.73 m.

    RESULTS: Substudy results will be analyzed in 2022.

    LIMITATIONS: It is not possible to mask patients or providers to the intervention; however, objective measures will be used to assess acute kidney injury.

    CONCLUSIONS: This substudy will provide generalizable estimates of the effect of a perioperative hypotension-avoidance strategy on the risk of acute kidney injury.


    © The Author(s) 2022.

    KEYWORDS: acute kidney injury, antihypertensive medication, hypotension, mean arterial pressure, noncardiac surgery

    Publikations ID: 35024154
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt